Screener / SEC EDGAR /CIK 0001104506 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

INSMED Inc INSM

Compare with peers Embed
The 10-K against last year's

251 changes: 30 added, 19 removed, 155 reworded, 47 quiet changes

10-K Feb 19, 2026 vs Feb 20, 2025

10-K 0001104506-26-000009 (Feb 19, 2026) vs 10-K 0001104506-25-000009 (Feb 20, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

346 paragraphs · 25 new · 213 reworded · 12 gone · 10-K Feb 19, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 170 · 50% changed Every version of it
In addition, to date, only a small number of gene therapy products have been approved in the US, Europe or elsewhere, and regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. We may seek regulatory approval in territories outside the US and Europe, which may have their own regulatory authorities along with frequently changing requirements or guidelines. The regulatory review committees and advisory groups in the US, Europe and elsewhere, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Within the FDA, the Center for Biologics Evaluation and Research (CBER) regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Therapeutic Products, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. CBER works closely with the National Institutes of Health (the NIH) in connection with the development of gene therapy. The FDA has published specific guidance documents with respect to the development and approval of gene therapy products. For example, in January 2020, the FDA issued final guidance documents that updated draft guidance documents that were originally released in July 2018 to reflect recent advances in the field, and to set forth the framework for the development, review and approval of gene therapies. Amongst these guidance documents are final guidance documents that pertain to the development of gene therapies for the treatment of specific disease categories, including rare diseases of interest to Insmed, and to manufacturing and long-term follow-up issues relevant to gene therapy, among other topics. The For example, the FDA also issued a final guidance document in September 2021 describing the FDA’s approach for determining whether two gene therapy products are the same or are different for the purpose of orphan-drug designation and orphan-drug exclusivity. On January 11, 2026, the FDA announced information about what the agency called its “flexible approach” to overseeing chemistry, manufacturing and control requirements for cell and gene therapies, although applicable requirements remain rigorous. The FDA has continued to issue additional draft and final guidance documents on the development and manufacture of gene therapy products. In addition, the FDA can put an IND for a gene therapy study on clinical hold for several reasons, including, but not limited to, if the information in an IND is not sufficient to assess the potential risks in study subjects.
Paragraph 70 · 49% changed Every version of it
As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial. Additionally, we are required to submit periodic reports on the progress of this clinical trial. In the fourth quarter of 2020, we commenced the post-marketing confirmatory clinical trial program for ARIKAYCE in patients with MAC lung disease. The confirmatory clinical trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease using the PRO tool validated in the ARISE trial. The confirmatory clinical program is intended to fulfill the FDA’s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE. The trial completion timetable agreed upon with the FDA when the
Paragraph 276 · 49% changed Every version of it
We are a party to various agreements related to ARIKAYCE and our product candidates, including licensing agreements with PARI and AstraZeneca, which we view as material to our business. For additional information regarding the terms of these agreements, see Business—License and Other Agreements in Item 1 of Part I of this Annual Report on Form 10-K. These agreements impose a number of obligations on us and our business, including restrictions on our ability to freely develop or commercialize our product candidates and requirements to make milestone and royalty payments to our counterparties upon certain events. For example, under our license agreement with AstraZeneca, AstraZeneca retains a right of first negotiation pursuant to which it may exclusively negotiate with us before we can negotiate with a third party regarding any transaction to develop or commercialize brensocatib, subject to certain exceptions. While this right of first negotiation is not triggered by a change of control, it may impede or delay our ability to consummate certain other transactions involving brensocatib.
Paragraph 263 · 45% changed Every version of it
We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality and restrictive covenant agreements with our employees, consultants, advisors, collaborators, and other third parties and partners to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information or may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, third parties may independently develop or discover our trade secrets and proprietary information. Regulators also may disclose information we consider to be proprietary to third parties under certain circumstances, including in response to third-party requests for such disclosure under the Freedom of Information Act or comparable laws. Additionally, the FDA, as part of its Transparency Initiative, continues to consider whether to make additional information publicly available on a routine targeted, case-by-case basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time whether and how the FDA’s disclosure policies may change in the future. Further, several states have limited or prohibited the use of post-employment non-compete agreements and the Federal Trade Commission is evaluating a federal-level prohibition on such agreements, which could increase the difficulty of protecting trade secrets and other proprietary information. There are similar risks outside the US, such as the risk that a foreign regulatory agency would make available information we consider to be proprietary to third parties or the public, and the risks arising from other factors making it difficult to protect trade secrets, such as prohibitions or restrictions on post-employment non-compete agreements and other rules and regulations.
Paragraph 190 · 45% changed Every version of it
We are in the process of evaluating developing in-house clinical manufacturing capability for our gene therapy product candidates, but we expect to rely on third-party CMOs for manufacturing of all testing materials for the foreseeable future. Products intended for use in gene therapies are novel, complex and difficult to manufacture. As we shift towards in-house clinical manufacturing capability for our gene therapy product candidates, we may encounter delays in obtaining regulatory approval of our manufacturing processes or in complying with ongoing manufacturing regulatory requirements and applicable cGMP, including challenges related to producing adequate quantities of clinical grade materials that meet FDA, EMA, MHLW or other applicable standards or specifications with consistent and acceptable production yields and costs.
Paragraph 247 · 44% changed Every version of it
Our global operations expose us to risks associated with public health crises and pandemics, particularly as the patients we seek to treat suffer from serious diseases that may make them especially vulnerable. A pandemic, including a resurgence of COVID-19, pandemic may also have an adverse impact on our operations and supply chain as a result of (i) our or our third-party manufacturers’ employees or other key personnel becoming infected, (ii) preventive and precautionary measures that governments and we and other businesses, including our third-party manufacturers, are taking, such as border closures, prolonged quarantines and other travel restrictions, (iii) shortages of supplies necessary for the manufacture of ARIKAYCE, including as a result of government orders providing for the requisition of personal protective equipment and other medical supplies and equipment, and (iv) cold-chain storage and shipping limitations resulting from the need to prioritize delivery of vaccines, which could cause disruptions or delays in our ability to distribute ARIKAYCE due to lack of sufficient cold-chain storage and shipping capacity. Any of these circumstances could impact the ability of third parties on which we rely to manufacture ARIKAYCE or its components and our ability to perform critical functions, which could significantly hamper our ability to supply ARIKAYCE to patients. While we have experienced no disruption to date in our supply chain due to a pandemic, if we encounter delays or difficulties in the manufacturing process that disrupt our ability to supply ARIKAYCE, we may not be able to satisfy patient demand or we may experience a product stock-out, which would likely have a material adverse effect on our business.
Paragraph 101 · 43% changed Every version of it
These any of these events likely would adversely impact market acceptance and other risks associated with demand for ARIKAYCE and/or BRINSUPRI, which, in turn, may affect our international operations may materially ability to successfully commercialize ARIKAYCE and/or BRINSUPRI and adversely affect impact our business, financial condition, results of operations and prospects and the value of our common stock.
Paragraph 225 · 42% changed Every version of it
We have and will continue to expand, upgrade and develop our information technology capabilities, including our enterprise resource planning system, which was implemented through Oracle software in 2022, and a new enterprise-wide human capital management system, Workday, implemented in 2024. If we are unable to successfully continue upgrading or expanding our technological capabilities to support our growth or if there are deficiencies in the design or implementation of such capabilities, we may not be able to take advantage of market opportunities, manage our costs effectively, manage our inventory, maintain a secure data environment, file timely reports with the SEC, or otherwise efficiently manage our internal controls. In addition, costs, potential problems and interruptions associated with the implementation of new or upgraded systems and technology, or with maintenance or adequate support of existing systems, could also disrupt or reduce the efficiency of our operations. Moreover, many of our vendors provide their services to us via a cloud-based model instead of software that is installed on our premises. As a result, we depend upon our vendors to provide us with services that are always available and are free of errors or defects that could cause disruptions in our business processes. Any failure by such vendors to do so, or any disruption in our ability to access the Internet, could may materially and adversely affect our ability to manage our operations.

MD&A

61 paragraphs · 5 new · 37 reworded · 7 gone · 10-K Feb 19, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 13 · 42% changed
Amortization of intangible assets for both the years ended December 31, 2025 and 2024 was $6.0 million and 2023 $5.1 million, respectively. This increase was $5.1 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&D and due to amortization of the AstraZeneca milestones paid to PARI for the achieved upon FDA and EMA EC approvals of ARIKAYCE. BRINSUPRI in August 2025 and November 2025, respectively.
Paragraph 28 · 39% changed
We had cash and cash equivalents of $510.4 million as of December 31, 2025 as compared with $555.0 million as of December 31, 2024 as compared with $482.4 million 2024. In addition, as of December 31, 2023, an increase of $72.7 million. This increase was primarily due to our underwritten offering of common stock in May 2024, proceeds from the new ATM program, and maturities of marketable securities, partially offset by our cash used in operating activities. In addition, 2025, we had marketable securities of $919.6 million as compared to $878.8 million as of December 31, 2024 as compared to $298.1 million as of December 31, 2023, an increase of $580.7 million. This increase is due to our use of cash proceeds to purchase investments. 2024. Our working capital was $1.3 billion as of December 31, 2024 as compared to $703.4 million as of December 31, 2023. 2025 and 2024.
Paragraph 46 · 36% changed
Based on our current operating plan we anticipate that our cash and cash equivalents and marketable securities as of December 31, 2025 will enable us to fund our operations. We may need to raise additional capital to fund our operations, including the development and potential commercialization of brensocatib, continued commercialization of ARIKAYCE, current and future clinical trials related to ARIKAYCE, development of TPIP, our future product candidates, and the potential development, acquisition, to develop, acquire, in-license or co-promotion of co-promote other products or product candidates, including those that address orphan or serious diseases. diseases with significant unmet need. We expect that our future capital requirements may be substantial and will depend on many factors, including:
Paragraph 16 · 33% changed
Interest expense was $83.8 million for the year ended December 31, 2025 as compared to $84.9 million for the year ended December 31, 2024 as compared to $81.7 million for the year ended December 31, 2023. The increase 2024. This decrease was primarily due to a reduction in interest expense related to the $150.0 million Tranche B Term Loan borrowing redemptions of the outstanding 0.75% Convertible Senior Notes due 2028 (the 2028 Convertible Notes) in October 2024 the second quarter of 2025 and the increase outstanding 1.75% Convertible Senior Notes due 2025 (the 2025 Convertible Notes) in the Term Loan principal balance due to the capitalization third quarter of paid-in-kind interest 2024, partially offset by the interest reduction on income related to the Tranche A Term Loan. Swap Contract in 2024. See Note 10 - Debt and Note 11 - Royalty Financing Agreement in this Annual Report on Form 10-K for further details.
Paragraph 27 · 30% changed
We may need to raise additional capital Based on our current operating plan we anticipate that our cash and cash equivalents and marketable securities as of December 31, 2025 will enable us to fund our operations, the continued commercialization of ARIKAYCE, commercial readiness activities for the launch of brensocatib for the treatment of patients with bronchiectasis, if approved, clinical trials for brensocatib, TPIP, INS1201, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address serious diseases. operations. While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital to fund future development of our product candidates, and may do so through equity to develop, acquire, in-license or debt financing(s), strategic transactions co-promote other products or otherwise. product candidates, including those that address serious diseases with significant unmet need. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be expenses related to our commercialization efforts for ARIKAYCE and BRINSUPRI and development costs for our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and clinical-stage assets, and, to a lesser extent, expenses related to the clinical development of TPIP and INS1201, and our pre-clinical research programs.
Paragraph 23 · 30% changed
In May 2024, we completed an underwritten offering of 14,514,562 shares of our common stock at a public offering price of $51.50 per share. 1,893,203 of the shares of common stock were issued pursuant to the exercise in full of the underwriters' option to purchase additional shares. Our net proceeds from the sale of the shares, after deducting underwriting discounts and estimated offering expenses of $34.3 million, were $713.2 million.
Paragraph 31 · 28% changed
Net cash provided by financing activities was $1.3 billion $954.1 million and $168.4 $1,341.0 million for the years ended December 31, 2024 2025 and 2023, 2024, respectively. The increase in During the years ended December 31, 2025 and 2024, net cash provided by financing activities for the year ended December 31, 2024 as compared to 2023 is due to net cash consisted primarily of proceeds received from the issuance of common stock in our underwritten offering in May 2024, public equity offerings and proceeds from our terminated new ATM program, the exercise of stock options and the Employee Stock Purchase Plan (ESPP). During the year ended December 31, 2024, net cash provided by financing activities also included $150.0 million in proceeds from the Tranche B Term Loan, and proceeds from stock options and our Employee Stock Purchase Program (ESPP). Loan.
Paragraph 9 · 26% changed
We expect R&D expenses to increase in 2025 2026 relative to 2024 2025 primarily due to our clinical trial activities and related spend spend, including our confirmatory clinical trial of ARIKAYCE in a treatment setting for patients with MAC lung disease, our TPIP and brensocatib clinical trials, and other research efforts for our product candidates. INS1201 and INS1202 are included within other external R&D expenses.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors231 words changed in this paragraph; it is 32% similar to last year's version.
In addition, based price. We expect competition to increase as technological advances are made and commercial applications broaden. There are potential competitive products, both approved and in part on our successful phase 2b Willow trial in bronchiectasis, development, which include oral, systemic, or inhaled antibiotic products to treat chronic respiratory infections. For instance, certain entities have expressed interest in studying their products for lung disease and are seeking to advance studies in lung disease, including NTM lung disease caused by mycobacterial species other DPP1 inhibitors for the treatment of bronchiectasis. than MAC. We are not aware of at least two any entities currently conducting clinical trials for the treatment of bronchiectasis with a DPP1 inhibitor. refractory MAC lung disease or of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. If any of these our competitors develops a DPP1 inhibitor product that is more effective, safe, tolerable or convenient, or less expensive than ARIKAYCE, BRINSUPRI, or our product candidates, if approved, it would likely materially adversely affect our ability to generate revenue, should brensocatib ultimately be approved. If revenue. We also may face lower priced generic competitors if third-party payors encourage use of generic or lower-priced versions of our product or if competing products are imported into the US or other countries where we are unable may sell ARIKAYCE or BRINSUPRI. In addition, in an effort to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects put downward pressure on drug pricing, Congress and the value of FDA are working to facilitate generic competition, which could result in our common stock. experiencing competition earlier than otherwise would be the case.

Source: Item 1A, 10-K 0001104506-26-000009 vs Item 1A, 10-K 0001104506-25-000009

MD&A156 words changed in this paragraph; it is 48% similar to last year's version.
We may need to raise additional capital Based on our current operating plan we anticipate that our cash and cash equivalents and marketable securities as of December 31, 2025 will enable us to fund our operations, the continued commercialization of ARIKAYCE, commercial readiness activities for the launch of brensocatib for the treatment of patients with bronchiectasis, if approved, clinical trials for brensocatib, TPIP, INS1201, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address serious diseases. operations. While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital to fund future development of our product candidates, and may do so through equity to develop, acquire, in-license or debt financing(s), strategic transactions co-promote other products or otherwise. product candidates, including those that address serious diseases with significant unmet need. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be expenses related to our commercialization efforts for ARIKAYCE and BRINSUPRI and development costs for our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and clinical-stage assets, and, to a lesser extent, expenses related to the clinical development of TPIP and INS1201, and our pre-clinical research programs.

Source: Item 7, 10-K 0001104506-26-000009 vs Item 7, 10-K 0001104506-25-000009

Accounting Policies122 words changed in this paragraph; it is 70% similar to last year's version.
Business Combinations and Asset Acquisitions - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. 805).

Source: 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0001104506-26-000009 vs 10-K text, Note 2 – Summary of Significant Accounting Policies, 10-K 0001104506-25-000009

Legal Proceedings29 words changed in this paragraph; it is 83% similar to last year's version.
In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total $ 66.6 63.0 million. These amounts do not represent the Company's entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend amounts or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment.

Source: Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001104506-26-000009 vs Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001104506-25-000009

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of INSM's Risk Factors and MD&A, 10-K Feb 19, 2026 against 10-K Feb 20, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
In addition, advertising and promotion of any product candidate that obtains approval in the US is heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services’ Office of Inspector General, state attorneys general, members of Congress, other government agencies and the public. While physicians may prescribe products for off-label uses as the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing authorization has not been obtained. Companies may only share truthful and not misleading information that is otherwise consistent with a product’s FDA-approved labeling. Violations, including promotion of our products for unapproved (or off-label) uses, may be subject to untitled or warning letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval in their respective jurisdictions.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
Furthermore, on September 9, 2025, President Trump issued a Memorandum directing the US Department of Health and Human Services, or HHS, to “ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements.” The same day, the FDA declared that it will no longer tolerate what it characterized as “deceptive practices” in prescription drug advertising and that the agency would “aggressively deploy” its available enforcement tools with “heightened scrutiny” of fair balance and disclosures in social media promotions. The FDA issued a generic “notice letter” to all holders of approved drug and biologic applications, including us, directing such companies to “remove any noncompliant advertising and bring all promotional communications into compliance.” Any failure by us to comply with any of these requirements may lead to onerous government investigations or enforcement action or otherwise materially harm our business.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
In addition, the policies of the FDA, the EMA, the MHLW, and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, may adversely affect our business, financial condition and results of operations. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which may adversely affect our business, prospects and ability to achieve or sustain profitability.
Read it in 10-K Feb 19, 2026 at sec.gov
Show the other 67
AddedRisk Factors
Furthermore, professional societies, practice management groups, private health and science foundations and other organizations publish guidelines or recommendations to the healthcare and patient communities relating to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients and healthcare providers could result in decreased use of our products.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedRisk Factors
We may be unable to obtain, or may not be able to maintain, regulatory exclusivity for our products or product candidates, including exclusivity under the Hatch-Waxman Act, orphan drug exclusivity, Generating Antibiotic Incentives Now Act exclusivity, or pediatric exclusivity. Even if granted, such exclusivity may be limited in scope or duration and may not prevent competitors from developing or marketing competing products. For example, while BRINSUPRI is eligible for five-year new chemical entity exclusivity, which should block submission of an Abbreviated New Drug Application (ANDA) or 505(b)(2) with the same active moiety for five years (or four years, if a paragraph IV certification of patent invalidity, unenforceability, or non-infringement is filed), if another sponsor submits a 505(b)(1) application for a drug containing the same active moiety, BRINSUPRI’s regulatory exclusivity would not block submission of that product. The loss or expiration of any exclusivity period could allow competitors to introduce generic or other competing products, which may significantly reduce our revenues and adversely affect our business, financial condition, and results of operations.
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedRisk Factors
•We may not be successful in clinical trials or in obtaining regulatory approvals required to expand the indications for ARIKAYCE, which may materially adversely affect our prospects and the value of our common stock.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
•Failure to obtain or maintain regulatory approval or clearance of our product devices, including Lamira, as a delivery system for ARIKAYCE, and the dry powder delivery system for TPIP, could materially harm our business.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Our long-term viability and growth depend on the continued successful commercialization of ARIKAYCE, our only approved product. ARIKAYCE was approved in the US for the treatment of MAC lung disease as part of a combination
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
used to carry the genetic material, which could adversely affect our ability to obtain and maintain regulatory approvals for and commercialize any gene therapy products we may develop.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
In January 2024, the US House of Representatives introduced the BIOSECURE Act (H.R. 7085) and the Senate advanced a substantially similar bill (S.3558), which legislation, if passed and enacted into law, would potentially restrict our ability to utilize certain products and services from, or otherwise collaborate with, any "biotechnology company of concern,” in the performance of a government contract or subcontract. Although the House version of the bill passed on September 9, 2024, the legislation ultimately did not pass before the end of the last session of Congress. It is possible that the BIOSECURE Act could be raised again in some form in this new and current session of Congress, either as a standalone bill or as part of broader legislation, and focus on these issues is expected to continue. We do business with companies in China and it is possible some of our contractual counterparties could be impacted by this legislation.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Compounds, products or
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
business in the form of higher costs for labor and materials, possible reductions in pharmaceutical industry-wide spending on research and development and acquisitions and higher costs of capital.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical, scientific and factual questions, and our success depends in large part on our ability to protect our
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
change, or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, including our NDA submission for brensocatib, which could have a material adverse effect on our business.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
In May 2021, we completed an underwritten offering of 0.75% convertible senior notes due in 2028 (the 2028 Convertible Notes). The 2028 Convertible Notes may be convertible into common stock at an initial conversion rate of 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes. We sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters’ option to purchase additional 2028 Convertible Notes, resulting in net proceeds of approximately $559.3 million. Holders of the 2028 Convertible Notes may convert their 2028 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 1, 2028, only under certain circumstances, which circumstances have existed each quarter since the third quarter of 2024. On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2028 Convertible Notes at any time. Upon conversion of the 2028 Convertible Notes, we may deliver cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
conversion of the 2028 Convertible Notes could be used to satisfy short positions, or the anticipated conversion of the 2028 Convertible Notes into shares of our common stock could depress the price of our common stock. The future issuance of any additional shares of common stock will dilute our current shareholders and may create downward pressure on the value of our shares. The potential for the issuance of a significant amount of our common stock pursuant to the 2028 Convertible Notes could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, could also hinder our ability to raise additional equity capital at a time and price that we deem reasonable or appropriate.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedRisk Factors
Additionally, a substantial portion of our commercial supply of ARIKAYCE is currently manufactured in Canada and, if approved, we expect that Canada, our commercial supply of brensocatib will BRINSUPRI is also be manufactured in Canada. Canada, and our supply of treprostinil palmitil, the treprostinil prodrug present in TPIP, is currently dependent on a single supplier located in Taiwan.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
We have invested and continue to invest significant efforts and financial resources in the commercialization of ARIKAYCE, ARIKAYCE and our ability to continue to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE from the FDA by conducting an appropriate confirmatory post-marketing study. BRINSUPRI.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Even if brensocatib or another any of our product candidate candidates is approved, or if ARIKAYCE is approved outside of the US, Europe and Japan, or if BRINSUPRI is approved outside of the US and the EU, regulators may limit the indications for which the product may be marketed, require extensive warnings on the product labeling labeling, require other burdensome risk mitigation measures, such as distribution restrictions, or require expensive and time-consuming additional clinical trials or reporting as conditions of approval.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
While we have obtained accelerated approval for ARIKAYCE in the US, approval for ARIKAYCE in Europe and Japan and approval for BRINSUPRI in the US and approval in the EU and Japan, EU, seeking regulatory approvals for brensocatib and any future regulatory approvals for our other product candidates candidates, as well as approval for ARIKAYCE in front-line NTM lung disease or for ARIKAYCE or BRINSUPRI in other jurisdictions presents significant obstacles.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
We may not be able to obtain regulatory approvals for brensocatib, or for our other product candidates and we may not be able to receive approval for ARIKAYCE in front-line NTM lung disease disease, for ARIKAYCE or BRINSUPRI in new markets. additional markets or for our product candidates.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
At this time, while we believe that ARIKAYCE will be excluded from negotiation due to its orphan drug designation, we We cannot predict other potential implications the IRA provisions will have on our business or the pricing of brensocatib or TPIP, our product candidates, if approved, or any approved.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors’ products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could any claims that gene therapy is unsafe, or gene therapy being unable to gain the acceptance of the public or the medical community may further adversely impact our product candidates in the form of increased government regulation, unfavorable public perception, lack of physician adoption, the need for additional testing or monitoring, potential regulatory delays, stricter labeling requirements, and a decrease in demand.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Our ability to generate revenue depends on the success of commercial sales of ARIKAYCE; ARIKAYCE and BRINSUPRI; however, we do not anticipate our revenue from achieving profitability for the sale of ARIKAYCE will be sufficient for us to become profitable without reductions in our operating expenses. foreseeable future.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Despite receiving FDA, EC and Japan's Japan’s MHLW approval of ARIKAYCE, ARIKAYCE and FDA and EC approval of BRINSUPRI for the specified indications, market acceptance may vary among physicians, patients, third-party payors or others in the healthcare community. community and is dependent on a number of factors, including the following:
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial for ARIKAYCE in patients with MAC lung disease, which we commenced in the fourth quarter of 2020, and submit periodic reports on the progress of this clinical trial.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
Furthermore, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material, which may adversely affect our ability to obtain and maintain regulatory approvals for and commercialize any gene therapy products we may develop.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedRisk Factors
If our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP, BRINSUPRI, or our other product candidates are overstated or data we have used to identify physicians is prove inaccurate, our ability to earn generate revenue to support our business could may be materially adversely affected.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
If we fail to comply with these laws, we could may be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could may adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Resolving such delays could may force us or third parties to incur significant costs, limit our allowed activities or the allowed activities of third parties, diminish any competitive advantages that we or our third parties may attain or adversely affect our ability to receive royalties, any of which could may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Based on feedback and in alignment with the FDA, we have determined that the primary endpoint for the ENCORE trial will would include eight questions from the QOL-B respiratory domain PRO.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Both of these risks, in turn, could may affect our ability to successfully commercialize ARIKAYCE and BRINSUPRI and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
In either circumstance, even if we obtain regulatory approval, we may be unable to commercialize the product on a scale sufficient to generate significant revenue from such product candidates, which could may have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, may be interpreted differently if additional data are disclosed, and are subject to audit and verification procedures that could may result in material changes in the final data.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could may result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities.
Read it in 10-K Feb 19, 2026 at sec.gov
Quiet changesRisk Factors
In addition, with respect to our product candidates, our manufacturers and their facilities are subject to pre-approval cGMP inspection by the FDA and other regulatory authorities, and the findings of the cGMP inspection could may result in a failure to obtain, or a delay in obtaining, regulatory approval for future product candidates.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
All product costs for BRINSUPRI incurred prior to FDA approval on August 12, 2025 were expensed as R&D expenses. We expect our cost of product revenues (excluding amortization of intangible assets) to benefit during 2026 and beyond, as we sell through inventory that was expensed prior to FDA approval of BRINSUPRI.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
In December 2025, we acquired the global rights to OpSCF (renamed INS1148) from Opsidio. The Opsidio shareholders may become entitled to receive contingent payments up to an aggregate of $382 million in cash upon the achievement of certain development, regulatory and sales milestones, as well as earnout payments based upon a low to mid single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
In June 2023, we acquired all of the issued and outstanding share capital of Adrestia, a privately held, pre-clinical stage company. Adrestia's former shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.gov
AddedMD&A
In January 2023, we acquired Vertuis, a privately held, pre-clinical stage company. The Company is obligated to pay the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions. See Note 15 - Licenses and Other Agreements in this Annual Report on Form 10-K for further details.
Read it in 10-K Feb 19, 2026 at sec.gov
RemovedMD&A
•The cost of product revenues (excluding amortization of intangibles) increased $20.2 million, or 30.8%, as compared to the prior year primarily as a result of the growth in ARIKAYCE sales;
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
In May 2021, we completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes pursuant to an indenture between the Company and Wells Fargo Bank, National Association, as trustee (the Indenture). Net proceeds from the offering, after deducting underwriting discounts and offering expenses of $15.7 million, were $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes are convertible into common stock of the Company under certain circumstances described in the Indenture. On July 1, 2024 and October 1, 2024, the 2028 Convertible Notes became convertible, through the end of the third quarter of 2024 and fourth quarter of 2024, respectively, by the holders of such notes due to the satisfaction of the Stock Price Convertibility Trigger applicable to such notes. The current conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). We have elected to settle any conversions of the 2028 Convertible Notes in shares of common stock. For more information, see Note 10 - Debt in our notes to the consolidated financial statements.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
We have a licensing agreement with PARI for the use of optimized Lamira for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, we have rights under several US and
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
In 2004 and 2009, we entered into research funding agreements with CFFT whereby we received $1.7 million and $2.2 million, respectively, in research funding for the development of ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, we owe milestone payments to CFFT of $13.4 million in the aggregate payable through 2025, of which $10.4 million has been paid as of December 31, 2024. Furthermore, if certain global sales milestones were met within five years of the commercialization of ARIKAYCE, we would have owed up to an additional $3.9 million. Through December 31, 2024, we have met and paid $1.7 million of these additional global sales milestone payments.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedMD&A
This increase was primarily due to the $65.8 $76.7 million increase in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount, a $21.2 $45.5 million increase in manufacturing expense, and the $40.0 million up-front cash consideration in connection with the acquisition of INS1148, partially offset by the $12.5 million AstraZeneca milestone upon our release of an official public statement that we intended to file an NDA for brensocatib, and a $9.5 million increase brensocatib in regulatory, quality assurance, and medical affairs expense, partially offset by the $86.7 million non-cash asset acquisition cost of Adrestia and Vertuis in 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
We may need to raise additional capital to fund our operations, including the development and potential commercialization of brensocatib, continued commercialization of ARIKAYCE, current and future clinical trials related to ARIKAYCE, development of TPIP, our future product candidates, and the potential development, acquisition, to develop, acquire, in-license or co-promotion of co-promote other products or product candidates, including those that address orphan or serious diseases. diseases with significant unmet need.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The net Net cash used in operating activities during was $935.0 million and $683.9 million for the years ended December 31, 2024 2025 and 2023 2024, respectively, which was primarily for the driven by commercial, clinical, and manufacturing activities related to ARIKAYCE, commercial and commercial readiness activities for BRINSUPRI, as well as other SG&A expenses and expenses, clinical trial expenses related to brensocatib and TPIP. TPIP, and the $40.0 million acquisition of INS1148.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital to fund future development of our product candidates, and may do so through equity to develop, acquire, in-license or debt financing(s), strategic transactions co-promote other products or otherwise. product candidates, including those that address serious diseases with significant unmet need.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be expenses related to our commercialization efforts for ARIKAYCE and BRINSUPRI and development costs for our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and clinical-stage assets, and, to a lesser extent, expenses related to the clinical development of TPIP and INS1201, and our pre-clinical research programs.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
The increase in cash used for investing activities for During the year ended December 31, 2024 as compared to 2023 is due to the 2024, net cash used in investing activities consisted primarily of purchases of marketable securities, partially offset by maturity maturities of certain marketable securities.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Cost of product revenues (excluding amortization of intangibles) were $122.9 million for the year ended December 31, 2025 as compared to $85.7 million for the year ended December 31, 2024 as compared to $65.6 million for the year ended December 31, 2023, 2024, an increase of $20.2 $37.2 million, or 30.8%. 43.4%.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
R&D expenses were $771.1 million for the year ended December 31, 2025 as compared to $598.4 million for the year ended December 31, 2024 as compared to $571.0 million for the year ended December 31, 2023, 2024, an increase of $27.4 $172.7 million, or 4.8%. 28.9%.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
We had cash and cash equivalents of $510.4 million as of December 31, 2025 as compared with $555.0 million as of December 31, 2024 as compared with $482.4 million as of December 31, 2023, an increase of $72.7 million. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
In addition, as of December 31, 2025, we had marketable securities of $919.6 million as compared to $878.8 million as of December 31, 2024 as compared to $298.1 million as of December 31, 2023, an increase of $580.7 million. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Interest expense was $83.8 million for the year ended December 31, 2025 as compared to $84.9 million for the year ended December 31, 2024 as compared to $81.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.gov
RewordedMD&A
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates. rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance.
Read it in 10-K Feb 19, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.